Michael Wang, MD; University of Texas MD Anderson Cancer Center 5Live #ASCO20
8:25
Key Insights on Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.
Mantle Cell Lymphoma
Michael Wang, MD; University of Texas MD Anderson Cancer Center 5Live #ASCO20
Key Insights on Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.
Mantle Cell Lymphoma Similar Videos
Similar Videos
